Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

PR Newswire 7 days ago

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

PR Newswire 9 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire 12 days ago

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

PR Newswire March 28, 2024

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

PR Newswire March 26, 2024

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

PR Newswire March 18, 2024

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire March 1, 2024

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

PR Newswire February 27, 2024

Syndax Announces Participation at Two Upcoming Investor Conferences

PR Newswire February 26, 2024

Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024

PR Newswire February 20, 2024

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire February 2, 2024

Syndax Announces Participation at Two Upcoming Investor Conferences

PR Newswire February 1, 2024

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire January 5, 2024

Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 2, 2024

Syndax Highlights Recent Updates and Anticipated 2024 Milestones

PR Newswire January 2, 2024

Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

PR Newswire December 19, 2023

Syndax Announces Pricing of $200 Million Public Offering of Common Stock

PR Newswire December 14, 2023

Syndax Announces Proposed $150 Million Public Offering of Common Stock

PR Newswire December 14, 2023

Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

PR Newswire December 12, 2023

Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials

PR Newswire December 11, 2023